A Randomized, Double-Blind, Phase 3 Study to Evaluate the Efficacy and Safety of Vedolizumab Intravenous as Maintenance Therapy in Pediatric Subjects With Moderately to Severely Active Ulcerative Colitis Who Achieved Clinical Response Following Open-Label Vedolizumab Intravenous Therapy
Latest Information Update: 04 Aug 2025
At a glance
- Drugs Vedolizumab (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Takeda; Takeda Development Center Americas
Most Recent Events
- 18 Jul 2025 Status changed from active, no longer recruiting to completed.
- 20 Sep 2024 Status changed from recruiting to active, no longer recruiting.
- 05 Jun 2024 This trial has been Discontinued in Czechia according to European Clinical Trials Database record.